Biostem Technologies Inc
OTC:BSEM

Watchlist Manager
Biostem Technologies Inc Logo
Biostem Technologies Inc
OTC:BSEM
Watchlist
Price: 5.2 USD 4.21%
Market Cap: 87m USD

Relative Value

The Relative Value of one BSEM stock under the Base Case scenario is 22.96 USD. Compared to the current market price of 5.2 USD, Biostem Technologies Inc is Undervalued by 77%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BSEM Relative Value
Base Case
22.96 USD
Undervaluation 77%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
75
Median 3Y
1.4
Median 5Y
4
Industry
2.7
Forward
0.4
vs History
23
vs Industry
36
Median 3Y
2.4
Median 5Y
-8.5
Industry
21.6
Forward
19.9
vs History
25
vs Industry
35
Median 3Y
16.6
Median 5Y
-10.5
Industry
16.9
vs History
39
vs Industry
28
Median 3Y
33.7
Median 5Y
28.8
Industry
22.9
vs History
28
vs Industry
9
Median 3Y
1.7
Median 5Y
-2.1
Industry
2.3
vs History
92
vs Industry
79
Median 3Y
1.4
Median 5Y
4.4
Industry
3
Forward
0.2
vs History
92
vs Industry
85
Median 3Y
1.5
Median 5Y
5.9
Industry
5.6
vs History
28
vs Industry
40
Median 3Y
2.3
Median 5Y
-9.3
Industry
13.4
vs History
28
vs Industry
42
Median 3Y
2.3
Median 5Y
-9.3
Industry
16.7
Forward
1.4
vs History
30
vs Industry
38
Median 3Y
14.2
Median 5Y
-11.2
Industry
16.1
vs History
20
vs Industry
31
Median 3Y
10.2
Median 5Y
-20.9
Industry
18.9
vs History
92
vs Industry
39
Median 3Y
3
Median 5Y
8.3
Industry
2

Multiples Across Competitors

BSEM Competitors Multiples
Biostem Technologies Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Biostem Technologies Inc
OTC:BSEM
88.6m USD 0.3 3.3 2.5 2.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17 54.8 36.8 39.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
493.1B USD 5.4 19.7 16.1 20.8
CH
Roche Holding AG
SIX:ROG
271.9B CHF 4.4 28.9 12.3 14.3
UK
AstraZeneca PLC
LSE:AZN
217.1B GBP 5 31.1 108.7 159.1
US
Merck & Co Inc
NYSE:MRK
273.3B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
217.8B CHF 4.9 18.9 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.4 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
145B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
Biostem Technologies Inc
OTC:BSEM
Average P/E: 22.5
3.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.8
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.7
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
3%
5.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Biostem Technologies Inc
OTC:BSEM
Average EV/EBITDA: 400.2
2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Biostem Technologies Inc
OTC:BSEM
Average EV/EBIT: 1 712.6
2.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5